Amphastar Pharmaceuticals (AMPH)

• Market cap: $1.12B
• 1 day: -0.37%
• 5 days: 3.52%
• 1 month: -15.80%
• 3 months: -32.88%
• 6 months: -51.93%
• Year to date: -32.87%
• 1 year: -40.82%
• 5 years: 44.01%
• 10 years: 68.81%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Employees: 2,028

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

220% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $318K

0.56% more ownership

Funds ownership: 72.61% [Q3] → 73.17% (+0.56%) [Q4]

5% less funds holding

Funds holding: 276 [Q3] → 262 (-14) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 100

24% less capital invested

Capital invested by funds: $1.71B [Q3] → $1.31B (-$406M) [Q4]

25% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 48

67% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $32 31% upside
• Avg. target: $32 31% upside
• High target: $32 31% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Piper Sandler David Amsellem 56% 1-year accuracy 18 / 32 met price target

31% upside $32

Neutral Maintained

21 Mar 2025